Oncotarget: Researchers identify novel therapeutic strategy for drug-resistant thyroid cancers
(Chempetitive Group) New findings by a Harvard Medical School team suggest that palbociclib, a drug that is FDA-approved to treat advanced breast cancer, may be able to overcome vemurafenib resistance in PTC.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Harvard | International Medicine & Public Health | Thyroid | Thyroid Cancer